AstraZeneca (LSE: AZN) has announced that the asthma candidate tralokinumab, under development by the Anglo-Swedish firm’s biotech arm MedImmune, has failed to reach its primary endpoint in a pivotal trial.
Compared with placebo, no significant improvement was observed in the overall population of patients, using a commonly-used measure.
A subgroup of patients will now be the focus for a future analysis, as part of a second, ongoing Phase III trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze